COCP News and Press, Cocrystal Pharma Inc. From 11/09/23

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 inhibitor CC-42344 in an oral pr...

BOTHELL, Wash., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge trial with its broad-sp...

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease in...

2023-08-14 13:54:56 ET Cocrystal Pharma press release ( NASDAQ: COCP ): Q2 GAAP EPS of -$0.50. Cocrystal reported unrestricted cash as of June 30, 2023 of $32.4 million, compared with $37.1 million as of December 31, 2022. For further details see: Cocrystal Pharm...

On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza A Selected the novel protease inhibitor CDI-988 as development lead in the oral norovirus progra...

F irst dual coronavirus - norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against noroviruses including GII.4 pandemic strains N o approved treatments or vacci...

2023-05-31 08:27:50 ET Cocrystal Pharma ( NASDAQ: COCP ), a biotech focused on antiviral therapies, announced Wednesday that the company received approval to conduct a Phase 1 trial for its oral COVID-19 therapy CDI-988 in Australia. The permission from the Australian Human Rese...

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces approval from the Australian Human Research Ethics Committee (HREC) to conduct a Phase 1 study with its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a pot...

2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...

2023-05-15 09:58:13 ET Cocrystal Pharma press release ( NASDAQ: COCP ): Q1 GAAP EPS of -$0.64 misses by $0.05 . Cocrystal reported unrestricted cash as of March 31, 2023 of $34.0 million, compared with $37.1 million as of December 31, 2022. Research and development...